| Upcoming events on MERCK & CO., INC. |
|
| 02/04/21 | 06:45am | | FY 2020 Earnings Release |
| 02/04/21 | 08:00am | | FY 2020 Earnings Call |
| 04/29/21 | | Q1 2021 Earnings Release |
| 04/29/21 | 08:00am | | Q1 2021 Earnings Call |
|
| Past events on MERCK & CO., INC. |
|
| 01/11/21 | 04:30pm | | JP Morgan Healthcare Conference |
| 12/14/20 | | Ex-dividend day for |
| 12/02/20 | 09:40am | | Evercore ISI HealthCONx Conference |
| 11/09/20 | | ABRCMS Virtual Conference |
|
| Upcoming sector events for MERCK & CO., INC. |
|
|
| |
|
| Past sector events for MERCK & CO., INC. |
|
|
|
|
|
| Annual results | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 (e) |
Sales
M $ |
Released
Forecast
Spread | 39 498
39 600
-0,26% | 39 807
39 991
-0,46% | 40 122
40 205
-0,21% | 42 294
42 234
0,14% | 46 840
46 818
0,05% |
48 203
|
Operating income
(EBITDA)
M $ |
Released
Forecast
Spread | 19 757
15 314
29% | 19 154
19 083
0,37% | 15 131
15 472
-2,2% | 15 781
15 310
3,1% | 19 572
18 761
4,3% |
19 888
|
Operating profit
(EBIT)
M $ |
Released
Forecast
Spread | 13 382
13 401
-0,14% | 13 713
13 698
0,11% | 13 551
13 722
-1,2% | 13 926
13 815
0,80% | 15 920
16 276
-2,2% |
17 403
|
Pre-Tax Profit
(EBT)
M $ |
Released
Forecast
Spread | 5 401
6 210
-13% | 7 499
7 288
2,9% | 6 747
6 720
0,40% | 8 701
8 296
4,9% | 11 464
12 277
-6,6% |
14 782
|
Net income
M $ |
Released
Forecast
Spread | 4 442
4 786
-7,2% | 5 691
5 779
-1,5% | 2 568
5 147
-50% | 6 220
6 462
-3,7% | 9 843
9 957
-1,1% |
12 158
|
EPS
$ |
Released
Forecast
Spread | 1,56
1,64
-4,6% | 2,04
2,03
0,57% | 0,93
1,85
-50% | 2,32
2,44
-5,0% | 3,81
3,83
-0,52% |
4,74
| | Announcement Date | 02/03/2016 | 02/02/2017 | 02/02/2018 | 02/01/2019 | 02/05/2020 | |
|
|
|
| Quarterly results | 2018 Q2 | 2018 Q3 | 2018 Q4 | 2019 Q1 | 2019 Q2 | 2019 Q3 | 2019 Q4 | 2020 Q1 | 2020 Q2 | 2020 Q3 | 2020 Q4 (e) | 2021 Q1 (e) | 2021 Q2 (e) | 2021 Q3 (e) | 2021 Q4 (e) |
Sales
M $ |
Released
Forecast
Spread | 10 465
10 304
1,6% | 10 794
10 888
-0,86% | 10 998
10 929
0,63% | 10 816
10 452
3,5% | 11 760
10 943
7,5% | 12 397
11 593
6,9% | 11 868
11 927
-0,49% | 12 057
11 458
5,2% | 10 872
10 657
2,0% | 12 551
12 213
2,8% |
12 656
|
12 829
|
12 589
|
13 210
|
13 036
|
Operating income
(EBITDA)
M $ |
Released
Forecast
Spread | 3 861
3 752
2,9% | 4 830
4 170
16% | 4 064
3 762
8,0% | 4 324
3 759
15% | 4 665
4 072
15% | 5 474
4 639
18% | 4 336
4 676
-7,3% | 4 802
4 715
1,8% | 4 707
3 911
20% | 5 744
4 862
18% |
4 611
|
5 512
|
5 502
|
5 618
|
5 291
|
Operating profit
(EBIT)
M $ |
Released
Forecast
Spread | 3 367
3 421
-1,6% | 3 769
3 720
1,3% | 3 489
3 371
3,5% | 3 823
3 390
13% | 4 070
3 646
12% | 4 629
3 989
16% | 3 400
3 777
-10,0% | 3 981
4 205
-5,3% | 3 659
3 238
13% | 4 892
4 342
13% |
4 053
|
4 838
|
4 345
|
4 943
|
4 929
|
Pre-Tax Profit
(EBT)
M $ |
Released
Forecast
Spread | 2 086
2 529
-18% |
|
| 3 067
2 984
2,8% |
|
|
|
|
|
|
|
|
|
|
|
Net income
M $ |
Released
Forecast
Spread | 1 707
1 950
-12% | 1 950
| 1 827
|
|
| 1 901
2 546
-25% | 2 357
2 458
-4,1% | 3 219
2 856
13% | 3 002
2 323
29% | 2 941
2 575
14% |
2 773
|
|
|
|
|
EPS
$ |
Released
Forecast
Spread | 0,63
0,72
-13% | 0,73
0,84
-13% | 0,69
0,85
-19% | 1,12
0,88
27% | 1,03
0,99
4,0% | 0,74
0,96
-23% | 0,92
0,94
-1,8% | 1,26
1,12
13% | 1,18
0,91
29% | 1,16
1,02
14% |
1,05
|
1,03
|
0,98
|
0,93
|
1,02
| | Announcement Date | 07/27/2018 | 10/25/2018 | 02/01/2019 | 04/30/2019 | 07/30/2019 | 10/29/2019 | 02/05/2020 | 04/28/2020 | 07/31/2020 | 10/27/2020 | | | | | |
|
Financial data source
© 2021 S&P Global Market Intelligence
|
|
© 2021 Factset
|
|
|
|
Merck to move COVID-19 treatment into large trials, sees sales recovering this year |
|
MERCK AND COMPANY
Leader in oncology, modest valuation |
Net sales (Year) - Rate of surprise
EPS (Year) - Rate of surprise
Net sales (Quarter) - Rate of surprise
EPS (Quarter) - Rate of surprise
|
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
Previous period
